Molecular and Cellular Correlates of Methotrexate Response in Childhood Acute Lymphoblastic Leukemia

References

• Margolin J. F., Poplack D. G., Pizza P. A. Acute lymphoblastic leukemia. In: Principles and Practice of Pediatric Oncology, D. G. Poplack. J. B. Lippincon Co, Philadelphia 1997
   Google Scholar
• Kersey J. H. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997; 90: 4243–4251
   PubMed Web of Science ®Google Scholar
• Pui C. H., Evans W. E. Aute lymphoblastic leukemia. N. Engl. J. Med. 1998; 339: 605–615
   PubMed Web of Science ®Google Scholar
• Farber S., Diamond L., Mercer R. D., Sylvester R. F., Wolff V. A. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-ami-nopteroyl glutamic acid (aminopterin). N. Eng. J. Med. 1948; 238: 787–793
   PubMed Web of Science ®Google Scholar
• Borowitz M. J., Carroll A. J., Shuster J. J., Look A. T., Behm F. G., Pullen D. J., Land V. J., Steuber P., Crist W. M. Use of clinical and laboratory features to define prognostic subgroups in B-precursor acute lymphoblastic leukemia: experience of the Pediatric Oncology Group. Recent Results in Cancer Research 1993; 131: 257–267
   PubMedGoogle Scholar
• Pui C. H., Behm F. G., Crist W. M. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343–362
   PubMed Web of Science ®Google Scholar
• Smith M., Arthur D., Camitta B., Carroll A. J., Crist W., Gaynon P., Gelber R., Herema N., Korn E. L., Link M., Murphy S., Pui C. H., Pullen J., Reaman G., Sallan S. E., Sather H., Shuster J., Simon R., Trigg M., Tubergen D., Uckun F., Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J. Clin. Oncol. 1996; 14: 18–24
   PubMed Web of Science ®Google Scholar
• Shuster J. J., Falletta J. M., Pullen J., Crisf W. M., Humphrey B., Dowell B. L., Wharam M. D., Borowitz M. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 75: 166173
   Web of Science ®Google Scholar
• Pui C. H., Boyett J. M., Hancock M. L., Pratt C. B., Meyer W. H., Crist W. M. Outcome of treatment for childhood cancer in black as compared with white children. The St. Jude Children's Research Hospital experience. JAMA 1995; 273: 633–637
   Google Scholar
• Raimondi S. C. Current status of cytogcnetic research in childhood acute lymphoblastic leukemia. Blood 1993; 81: 2237–2251
   PubMed Web of Science ®Google Scholar
• Pui C. H., Cnst W. M., Look A. T. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990; 76: 149–1463
   Web of Science ®Google Scholar
• Uckun F. M., Sensel M. G., Sun L., Steinhen Trigg. M. E., Heerema N. A., Sather H. N., Reaman G. H., Gaynon P. S. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 735–746
   PubMed Web of Science ®Google Scholar
• Faderl S., Kantarjian H. M., Talpaz M., Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91: 3995–4019
   PubMed Web of Science ®Google Scholar
• Ziemin-van der Poel S., McCabe N. R., Gill H. J., Espi-Nosa R., Patel Y., Harden A., Rubinelli P., Smith S. D., LeBeau M. M., Rowley J. D., Diaz M. O. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc. Natl. Acad. Sci., U. S. A. 1991; 88: 10735–10739
   PubMed Web of Science ®Google Scholar
• De Klein A., Hagemeijer A., Bartram C. R., Houwen R., Hoefsloof L., Carbonell F., Chen L., Barnett M., Greaves M., Kleihauer E., Heisterkamp N., Groffen, Grosvels G. BCR rearrangment and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 1986; 68: 1369–1375
   PubMed Web of Science ®Google Scholar
• Kunrock R., Shtalrid M., Romero P., Loetzer W. S., Talpaz M., Trujillo J. M., Blick M., Beran M., Gutterman J. U. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukemia. Nature 1987; 325: 631–635
   PubMed Web of Science ®Google Scholar
• Trueworthy R., Shuster J., Look T., Crist W., Borowitz M., Carroll A., Frankel L., Harris M., Wagner H., Haggard M., Mosijczuk A., Pullen J., Steuber P., Land V. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia in childhood: A Pediatric Oncology Group study. J. Clin. Oncol. 1992; 10: 606–613
   PubMed Web of Science ®Google Scholar
• Raimondi S. C., Pui C. H., Hancock M. L., Behm F. G., Filatov L., Rivera G. K. Heterogeneity of hyperdiploid (51–67) childhood acute lymphoblastic leukemia. Leukemia 1996; 10: 213–224
   PubMed Web of Science ®Google Scholar
• Harris M. B., Shuster J. J., Cmll A., Look A. T., Borow-Itz M. J., Crisf W. M., Nitschke R, Pullen J., Steuber C. P., Land V. J. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992; 79: 3316–3324
   PubMed Web of Science ®Google Scholar
• McLRan T. W., Ringold S., Neuberg D., Stegmaier K., Tantravahi R., Rib J., Koeffler H. P., Takeuchi S., Jans-Sen J. W. G., Seriu T., Bartram C. R., Sallan S. E., Gilliland D. G., Golub T. R. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252–4258
   PubMed Web of Science ®Google Scholar
• Nakao M., Yokota S., Horiike S., Taniwaki M., Kashima K., Sonoda Y., Koizumi S., Takaue Y., Matsushita X, Fujimoto T., Misawa S. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 1996; 10: 1463–1470
   PubMed Web of Science ®Google Scholar
• Shurtleff S. A., Buijs A., Behm F. G., Rubnitz J. E., Raimondi S. D., Hancock M. L., Chan G. C. F., Pui C. H., Grosveld G., Downing J. R. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985–1989
   PubMed Web of Science ®Google Scholar
• Harbott J., Viehmann S., Borkhardt A., Henze G., Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997; 90: 4933–4937
   PubMed Web of Science ®Google Scholar
• Raimondi S. C., Shurtleff S. A., Downing J. R., Rubnitz J., Mathew S., Hancock M., Hi C. H., Rivera G. K., Grosveld G. C., Behm F. G. 12p Abnormalities and the TEL gene (ETV6) in childhood acute lymphoblastic leukemia. Blood 1997; 90: 4559–4566
   PubMed Web of Science ®Google Scholar
• Rubnitz J. E., Downing C. H., Shurtleff Hi., Raimondi S. C., Evans W. E., Head D. R., Crist W. M., Rivera G. K., Hancock M. L., Boyett J. M., Buijs A, Grosveld G., Behm F. G. TEL rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J. Clin. Oncol. 1997; 15: 1150–1157
   PubMed Web of Science ®Google Scholar
• Golub T. R., Barker F. G., Bohlander S. K., Hiebert S. W., Ward D. C., Bray-Ward P., Morgan E., Raimondi S. C., Rowley J. D., Gilliland D. G. Fusion of the TEL gene on 12p13 to the AML1 gen on 21q22 in acute lymphoblastic leukemia. Roc. Natl. Acad. Sci. U. S. A. 1995; 92: 4917–4921
   PubMed Web of Science ®Google Scholar
• Romana S. P., Machaugge M., LeConiat M., Chumakov I., LePaslier D., Berger R., Bernard O. A. The t(12;21) of actue lymphoblastic leukemia results in a TEL-AML1 gene fusion. Blood 1995; 12: 3662–3670
   Google Scholar
• Nucifora G., Rowley J. D. AML1 and the 8;21 and 3;21 translocations in acute chronic myeloid leukemia. Blood 1995; 86: 1–14
   PubMed Web of Science ®Google Scholar
• Golub T. R., McLean T., Stegmaier K., Tomasson Carroll M, Gilliland D. G. The TEL gene and human leukemia. Biochim. Biophys. Acta 1996; 1288: M7–M10
   PubMed Web of Science ®Google Scholar
• Sato Y., Suto Y., Pietenpol J., Golub T. R., Gilliland D. G., Davis E. M., LeBeau M. M., Roberts J. M., Vogelstein B., Rowley J. D., Bohlander S. K. TEL and KIP1 define the smallest region of deletions on 12q22 in hematopoietic malignancies. Blood 1995; 86: 1525–1533
   PubMed Web of Science ®Google Scholar
• Pietenpol J. A., Bohlander S. K., Sato Y., Papadopoulos N., Liu B., Friedman C., Trask B. J., Toberts J. M., Kin-Zler K. W., Rowle JD, Vogelstein B. Assignment of the human p27KIP1 gene to 12p13 and its analysis in leukemias. Cancer Res. 1995; 55: 1206–1210
   PubMed Web of Science ®Google Scholar
• Hiebert S. W., Sun W., Davis J. N., Golub T. R., Shurtleff S., A J. R. D., Grosveld G., Roussel M., Gilliland D. G., Lenny N., Meyers S. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol. Cell. Biol. 1996; 16: 1349–1355
   PubMed Web of Science ®Google Scholar
• Meyers S., Lenny N., Sun W., Hiebert S. W. AML-2 is a potential target for transcriptional regulation by the t(8;21) and the t(12;21) fusion proteins in acute leukemia. Oncogene 1996; 13: 303–312
   PubMed Web of Science ®Google Scholar
• Drexler H. G. Review of alterations of the cyclindependent kinase inhibitor INK4 family genes p15, p16, p18, and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12: 845–859
   PubMed Web of Science ®Google Scholar
• Ohnishi H., Kawamura M., Ida K., Sheng X. M., Hanada R., Nobori T., Yamamori S., Hayashi Y. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995; 86: 1269–1275
   PubMed Web of Science ®Google Scholar
• Rasool O., Heyman M., Brandter L. B., Liu Y., Grander D., Soderhall S., Einhorn S. p15ink4B and p16ink4 gene inactivation in acute lymphoblastic leukemia. Blood 1995; 85: 3431–3436
   PubMed Web of Science ®Google Scholar
• Takeuchi S., Bartram C. R., Seriu T., Miller C. W., Tobler A., Janssen J. W., Reiter A., Ludwig W. D., Zimmerman M., Schwaller J., Lee E., Miyoshi I., Koeffler H. P. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia ofchildhood. Blood 1995; 86: 755–760
   PubMed Web of Science ®Google Scholar
• Iolascon A., Faienza M. F., Coppola B., Ragione ED., Schettini F., Biondi A. Homozygous deletions of cylin-dependent kinase inhibitor genes p161NK4A and p18, in childhood T-cell lineage acute lymphoblasic leukemias. Leukemia 1996; 10: 255–260
   PubMed Web of Science ®Google Scholar
• Nakao M., Yokota S., Kaneko H., Seriu T., Koizumi S., Takaue Y., Fujimoto T., Misawa S. Alterations of CDK2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T-lineage. Leukemia 1996; 10: 249–254
   PubMed Web of Science ®Google Scholar
• Heyman M., Rasool O., Borgonovo B. L., Liu Y., Grander D., Soderhall S., Gustavsson G Einhorn S. Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J. Clin. Oncol. 1996; 14: 1512–1520
   PubMed Web of Science ®Google Scholar
• Diccianni M. B., Yu J., Hsiao M., Mukherjee S., Shao L. E., Yu A. L. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994; 84: 3105–3112
   PubMed Web of Science ®Google Scholar
• Hsiao M. H., Yu A. L., Yeargin J., Ku D., Haas M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 1994; 83: 2922–2930
   PubMed Web of Science ®Google Scholar
• Goldman I. D., Matherly L. H. The cellular pharmacology of methotrexate. Pharmacol. Ther. 1985; 28: 77–102
   PubMed Web of Science ®Google Scholar
• Matherly L. H., Taub J. W. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leukemia and Lymphoma. 1996; 21: 359–368
   PubMed Web of Science ®Google Scholar
• Sirotnak F. M. Obligate genetic expression in tumor cells of a fetal membrane property mediating “folate” transport: Biological significance and implications of improved therapy of human cancer. Cancer Res. 1985; 45: 3992–4000
   PubMed Web of Science ®Google Scholar
• Henderson G. B., Zevely E. M. Transport routes utilized by L1210 cells for the influx and efflux of methotrexate. J. Biol. Chem. 1984; 259: 1526–1631
   PubMed Web of Science ®Google Scholar
• Saxena M., Henderson G. B. MOAT4, a novel multispecific organic-anion transporter for glucuronides and mercapturates in mouse L1210 cells and human erythro-cytes. Biochem. J. 1996; 320: 273–281
   PubMed Web of Science ®Google Scholar
• Moscow J. A., Gong M., He R., Sgagias M. K., Dixon K. H., Anzick S. L., Mettzer P. S., Cowan K. H. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res. 1995; 55: 3790–3794
   PubMed Web of Science ®Google Scholar
• Williams F. M. R., Flintoff W. F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J. Biol. Chem. 1995; 270: 2987–2992
   PubMed Web of Science ®Google Scholar
• Wong S. C., Proefke S. A., Bhushan A., Matherly L. H. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport defective Chinese hamster ovary cells. J. Biol. Chem. 1995; 270: 17468–17475
   PubMed Web of Science ®Google Scholar
• Zhang L., Wong S. C., Matherly L. H. Structure and organization of the human reduced folate carrier gene. Biochim. Biophys. Acta 1998; 1442: 389–393
   PubMed Web of Science ®Google Scholar
• Tolner B., Roy K., Sirotnak EM. Structural analysis of the human RFC-I gene encoding a folate transporter reveals multiple promoters and alternatively spliced transcripts with 5′ end hyeterogeneity. Gene 1998; 211: 331–341
   PubMed Web of Science ®Google Scholar
• Zhang L., Wong S. C., Matherly L. H. Transcript heterogeneity of the human reduced folate carrier results from the use of multiple promoters and variable splicing of alternative upstream exons, Biochem. J. 1998; 332: 773–780
   Google Scholar
• Blakley R. L. Dihydrofolate reductase. Chemistry and Biochemistry of Folates, R. L. Blakley, S. J. Benkovic. John Wiley and Sons, New York 1984; 191–253
   Google Scholar
• Fry D. W., Yalowich J. C., Goldman I. D. Rapid formation of polyglutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cells. J. Biol. Chem. 1982; 257: 1890–1896
   PubMed Web of Science ®Google Scholar
• Jolivet J., Schilsky R. L., Bailey B. D., Drake J. C., Chab-Ner B. A. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J. Clin. Invest. 1982; 70: 351–360
   PubMed Web of Science ®Google Scholar
• Chen L., Qi H., Korenberg J., Garrow T. A., Choi Y. J., Shane B. Purification and properties of human cytosolic folylpoly-γ-glutamate synthetase and organization, localization, and differential splicing of its gene. J. Biol. Chem. 1996; 271: 13077–13087
   PubMed Web of Science ®Google Scholar
• Allegra C. J., Chabner B. A., Drake J. C., Lutz R., Rod-Bard D., Jolivet J. Enhanced inhibition of thymidy-late synthase by methotrexate polyglutamates. J. Biol. Chem. 1985; 260: 9720–9726
   PubMed Web of Science ®Google Scholar
• Allegra C. J., Drake J., Jolivet J., Chabner B. A. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci., U. S. A. 1985; 82: 4881–4885
   PubMed Web of Science ®Google Scholar
• Schuetz J. D., Matherly L. H., Westin E. H., Goldman I. D. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate resistant murine L1210 leukemia cell line. J. Biol. Chem. 1988; 263: 9840–9847
   PubMed Web of Science ®Google Scholar
• Sirotnak F. M., Moccio D. M., Kelleher L. E., Goutas L. J. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate resistant L1210 clonal cell lines derived in viva. Cancer Res 1981; 41: 4447–4452
   PubMed Web of Science ®Google Scholar
• Biedler J. L., Albrecht A. M., Hutchinson D. J., Spengler B. A. Drug response, dihydrofolate reductase, and cytogenetics of amethopterin resistant Chinese hamster cells in vitro. Cancer Res. 1972; 32: 153–161
   PubMed Web of Science ®Google Scholar
• Schimke R. T. Gene amplification, drug resistance, and cancer. Cancer Res. 1984; 44: 1735–1742
   PubMed Web of Science ®Google Scholar
• Fischer G. A. Increased levels of folic acid reductase to amethopterin in leukemic cells. Biochem. Pharmacol. 1961; 7: 75–77
   PubMed Web of Science ®Google Scholar
• Hakala M. T., Zaknewski S. F., Nichol C. A. Relation of folic acid reductase to amethopterin resistance in cultured mammalian cells. J. Biol. Chem. 1961; 236: 952–958
   PubMed Web of Science ®Google Scholar
• Pizzorno G., Chang Y. M., McGuire J. J., Bertino J. R. Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Res. 1989; 49: 5275–5280
   PubMed Web of Science ®Google Scholar
• Pizzorno G., Mini E., Coronnello M., McGuire J. J., Moroson B. A., Cashmore A. R., Dreyer R. N., Lin J. T., Mazzei T., Periti P., Bertino J. R. Impaired poly-glutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res. 1988; 48: 2149–2155
   PubMed Web of Science ®Google Scholar
• McCloskey D. E., McGuire J. J., Russell C. A., Rowan B. G., Bertino J. R., Pizzorno G., Mini R. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol. Chem. 1991; 266: 6181–6187
   PubMed Web of Science ®Google Scholar
• Kellems R. E., Ah F. W., Schimke R. T. Regulation of folate reductase synthesis in sensitive and methotrexate resistant sarcoma 180 cells. In vitro translation and characterization of folate reductase mRNA. J. Biol. Chem. 1976; 251: 6987–6993
   PubMed Web of Science ®Google Scholar
• Alt R. W., Kellems R. E., Bertino J. R., Schimke R. T. Selective multiplication of dihydrofolate reductase genes in methotrexate resistant variants of cultured murine cells. J. Biol. Chem. 1978; 253: 1357–1370
   PubMed Web of Science ®Google Scholar
• Dolnick B. J., Berenson R. J., Bertino J. R., Kaufman R. J., Nunberg J. H., Schimke R. T. Correlation of dihydrofolate reductase elevation with gene amplification in a homogeneously staining chromosomal region in L5178y cells. J. Cell Biol. 1979; 83: 394–402
   PubMed Web of Science ®Google Scholar
• Li W. W., Ran J., Hochhauser D., Banejee D., Zielinski Z., Almasan A., Yin Y., Kelly R., Wahl G. M., Bertino J. R. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc. Natl. Acad. Sci., U. S. A. 1995; 92: 10436–10440
   PubMed Web of Science ®Google Scholar
• Hochhauser D., Schnieders B., Ercikan-Abali E., Gorlick R., Muise-Helmericks R., Li W. W., Fan J., Banejee D., Bertino J. R. Effect of cyclin DI overexpression on drug sensitivity in a human fibrosarcoma cell line. J. Natl. Cancer Inst. 1996; 88: 1269–1275
   PubMed Web of Science ®Google Scholar
• Wong S. C., McQuade R., Proefke S. A., Bhushan A., Matherly L. H. Human K562 transfectants expressing high levels of reduced folate carrier by exhibiting low transport activity. Biochem. Pharmacol. 1997; 53: 199–206
   PubMed Web of Science ®Google Scholar
• Gong M., Yess J., Connolly T., Ivy S. P., Ohnuma T., Cowan K. H., Moscow J. A. Molecular mechanism of antifolate transport-deficiency in a methotrexate resistant MOLT-3 human leukemia cell line. Blood 1997; 89: 2494–2499
   PubMed Web of Science ®Google Scholar
• Brigle K. E., Spinella M. J., Sierra E. E., Goldman I. D. Characterization ofa mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J. Biol. Chem. 1995; 270: 22974–22979
   PubMed Web of Science ®Google Scholar
• Roy K., Tolner B. M., Chiao J. H., Sirotnak F. M. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells. J. Biol. Chem. 1998; 273: 2526–2531
   Google Scholar
• Jansen G., Mauritz R., Drori S., Sprecher H., Kathmann I., Bunni M., Priest D. G., Noordhuis P., Schornagel J. H., Pinedo J. M., Peters G. J., Assaraf Y. G. A structurally altered human reduced folate canier with increased folic acid transpolt mediates a novel mechanism of antifolate resistance. J. Biol. Chem. 1998; 273: 30189–30198
   PubMed Web of Science ®Google Scholar
• Rhee M. S., Wang Y., Nair M. P., Galivan J. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res. 1993; 53: 2227–2230
   PubMed Web of Science ®Google Scholar
• Niethammer D., Diddens H., Gekeler V., Frese G., Hand-Gretinger R., Henze G., Schmidt H., Probst H. Resistance to methotrexate and multidrug resistance in childhood malignancies. Adv. Enzyme Reg. 1989; 29: 231–245
   PubMedGoogle Scholar
• Goker E., Waltham M., Kheradpour A., Lippett T., Mazumdar M., Elisseyeff Y., Schnieders B., Steinhertz P., Tan C., Berman E., Bertino J. R. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995; 86: 677–684
   PubMed Web of Science ®Google Scholar
• Matherly L. H., Taub J. W., Wong S. C., Simpson P. M., Ekizian E., Buck S., Williamson M., Amylon M., Pullen J., Camitta B., Ravindranath Y. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood 1997; 90: 578–589
   PubMed Web of Science ®Google Scholar
• Matherly L. H., Taub J. W., Ravindranath Y., Proefke S. A., Wong S. C., Gimotty P., Buck S., Wright J. E., Rosowsky A. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphocytic leukemia. Blood 1995; 85: 500–509
   PubMed Web of Science ®Google Scholar
• Rosowsky A., Wright J. E., Shapiro H., Beardsley P., Lazarus H. A new fluorescent dihydrofolate reductase probe for studies of methotrexate resistance. J. Biol. Chem. 1982; 257: 14162–14167
   PubMed Web of Science ®Google Scholar
• Yeargin J., Cheng J., Yu A. L., Gjerset R., Bogart M., Haas M. p53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T-cell acute lymphoblastic leukemia cell lines. J. Clin. Invest. 1993; 91: 2111–2117
   PubMed Web of Science ®Google Scholar
• Marks D. I., Kurz B. W., Link M. P., Ng E., Shuster J. J., Lauer S. J., Brodsky I., Haines D. S. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996; 87: 1155–1161
   PubMed Web of Science ®Google Scholar
• Imamura J., Miyoshi I., Koeffler H. P. p53 in hematologic malignancies. Blood 1994; 84: 2412–2421
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos C. E., Yang Y., Deleon E., McCown P., Stass S. A., Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617–2623
   PubMed Web of Science ®Google Scholar
• Marks D. I., Kurz B. W., Link M. P., Ng E., Shuster J. J., Lauer S. J., Brodsky I., Haines D. S. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996; 87: 1155–1161
   PubMed Web of Science ®Google Scholar
• Zhou M., Yeager A. M., Smith S. D., Findley H. W. Overexpression of the MDM2 gene by childhood acute lyrnphoblasic leukemia cells expressing the wild type p53 gene. Blood 1992; 85: 1608–1614
   Google Scholar
• Takeuchi S., Bartram C. R., Seriu T., Miller C. W., Tobler A., Janssen J. W., Reiter A., Ludwig W. D., Zimmerman M., Schwaller J., Lee E., Miyoshi I., Koeffler H. P. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16 /MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 755–760
   PubMed Web of Science ®Google Scholar
• Cayuela J. M., Madani A., Sanhes L., Stem M. H., Sigaux F. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1996; 87: 2180–2186
   PubMed Web of Science ®Google Scholar
• Hebert J., Cayuela J. M., Berkeley J., Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leuekemias. Blood 1994; 84: 4038–4044
   PubMed Web of Science ®Google Scholar
• Diccianni M. B., Batova A., Yu J., Vu T., Pullen J., Amylon M., Polock B. H., Yu A. L. Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. Leukemia Res. 1997; 21: 549–558
   PubMed Web of Science ®Google Scholar
• Heyrnan M., Rasool O., Borgonovo B. L., Liu Y., Grander D., Soderhall S., Gustavsson G Einhorn S. Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J. Clin. Oncol. 1996; 14: 1512–1520
   PubMed Web of Science ®Google Scholar
• Kees U., Burton P. R., Lu C., Baker D. L. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clincial outocme. Blood 1997; 89: 4161–4166
   PubMed Web of Science ®Google Scholar
• Zhang L., Taub J. W., Williamson M., Wong S. C., Hukku B., Pullen J., Ravindranath Y., Matherly L. H. Reduced folate canier gene expression in childhood acute lymphoblastic leukemia: Relationship to immu-nophenotype and ploidy. Clin. Cancer Res. 1998; 4: 2169–2177
   PubMed Web of Science ®Google Scholar
• Gorlick R., Goker E., Trippett T., Steinherz P., Elisseyeff Y., Mazumdar M., Flintoff W. F., Bertino J. R. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphoblastic leukemia and is associated with decreased reduced folate canier expression. Blood 1997; 89: 1013–1018
   PubMed Web of Science ®Google Scholar
• Goker E., Lin J. T., Trippett T., Elisseyeff Y., Tong W. P., Niedzwiecki D., Tan C., Steinherz P., Schweitzer B. I., Bertino J. R. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 1993; 7: 1000–1004
   PubMed Web of Science ®Google Scholar
• Masson E., Relling M. V., Synold T. W., Liu Q., Schuetz J. D., Sandlund J. T., Pui C. H., Evans W. E. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J. Clin. Invest. 1996; 97: 73–80
   PubMed Web of Science ®Google Scholar
• Synold T. W., Relling M. V., Boyett J. M., Rivera G. K., Sandlund J. T., Mahmoud H., Crist W. M., Pui C. H., Evans W. E. Blast cell methotrexate polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest. 1994; 94: 1996–2001
   PubMed Web of Science ®Google Scholar
• Whitehead V. M., Rosenblatt D. S., Vuchich M. J., Shuster J. J., Witte A., Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis ofchildhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 1990; 76: 44–49
   PubMed Web of Science ®Google Scholar
• Barredo J. C., Synold T. W., Laver J., Relling M. V., Pui C-H., Priest D. G., Evans W. E. Differences in constitutive and post-methotrexate folylpolyglutamate syn-thetase activity in B-lineage and T-lineage leukemia. Blood 1994; 84: 564–569
   PubMed Web of Science ®Google Scholar
• Whitehead V. M., Vuchich M. J., Lauer S. J., Mahoney D., Carroll A. J., Shuster J. J., Esseltine D. W., Payment C., Look A. T., Akabutu J., Bowen T., Taylor L. D., Camitta B., Pullen D. J. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts fmm children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1992; 80: 1316–1323
   PubMed Web of Science ®Google Scholar
• Whitehead V. M., Vuchich M. J., Cooky L., Lauer S. J., Mahoney D. H., Shuster J. J., Payment C., Bernstein M. L., Akabutu J. J., Bowen T., Kamen B. A., Watson M. S., Look A. T., Pullen D. J., Camitta B. Translocations invovlving chromosome 12p11–13, methotrexate metabolism, and outcome in childhood B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Clin. Cancer Res. 1998; 4: 183–188
   PubMed Web of Science ®Google Scholar
• Peeters M., Poon A. Down syndrome and leukaemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur. J. Pediatr. 1987; 146: 416–422
   PubMed Web of Science ®Google Scholar
• Longo G. S., Gorlick R., Tong W. P., Lin S., Steinherz P., Bertino J. R. Gamma-glutamyl hydrolase and folylpolyglutamate synthetase activities predict poly-glutamylation of methotrexate in acute leukemias. Oncol. Res. 1997; 9: 259–263
   PubMed Web of Science ®Google Scholar
• Rosenfeld C., Goutner A., Choquet C., Venuat A. M., Kayibanda B., Pico J. L. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature 1977; 267: 841–844
   PubMed Web of Science ®Google Scholar
• Uphoff C. C., MacLeod R. A. F., Denkmann S. A., Golub T. R., Borkhardt A., Janssen J. W. G., Drexler H. G. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines. Leukemia 1997; 11: 441–447
   PubMed Web of Science ®Google Scholar
• Livingstone L. R., White A, Sprouse J., Livanos E., Jacks T., Tlsty T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 1992; 70: 923–935
   PubMed Web of Science ®Google Scholar
• Yin Y., Tainsky M. A., Bischoff F. Z., Strong L. C., Wahl G. M. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937–948
   PubMed Web of Science ®Google Scholar
• Almasan A., Linke S. P., Paulson T. G., Huang L. C., Wahl G. M. Genetic instability as a consequence of inappropriate enby into and progression through S phase. Cancer Metastasis Reviews 1995; 14: 59–73
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathology 1995; 147: 545–560
   Web of Science ®Google Scholar
• Sherr C. J. Cancer cell cycles. Science 1996; 274: 1672–1677
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Bodis S., McClatchey A., Remington L., Ruley H. E., Fisher D. E., Housman E. E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807–810
   PubMed Web of Science ®Google Scholar
• Haffner R., Oren M. Biochemical properties and biological effects of p53. Cum. Opin. Cell Biol. 1995; 6: 853–858
   Google Scholar
• Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell 1992; 70: 523–526
   PubMed Web of Science ®Google Scholar
• Levine A. J. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–331
   PubMed Web of Science ®Google Scholar
• Agarwal M. L., Taylor W. R., Chernov M. V., Chernova O. B., Stark G. R. The p53 network. J. Biol. Chem. 1998; 273: 1–4
   PubMed Web of Science ®Google Scholar
• Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–3157
   PubMed Web of Science ®Google Scholar
• Cheng J., Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol. Cell. Biol. 1990; 10: 5502–5509
   PubMed Web of Science ®Google Scholar
• Wada H., Asada M., Nakazawa S., Itoh H., Kobayashi Y., Inoue T., Fukumuro K., Chan L. C., Sugita K., Hanada R., Akuta N., Kobayashi N., Mizutani S. Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 1994; 8: 53–59
   PubMed Web of Science ®Google Scholar
• Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245
   PubMed Web of Science ®Google Scholar
• Xiao Z. X., Chen J., Levine A. J., Modjtahedi N., Xing J., Sellers W. R., Livingston D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694–698
   PubMed Web of Science ®Google Scholar
• Martin K., Trouche D., Hagemeier C., Sorensen T. S., La Thangue N. B., Kouzarides T. Stimulation of E2Fl/DPl transcriptional activity by MDM2 oncoprotein. Nature 1995; 375: 691–694
   PubMed Web of Science ®Google Scholar
• Oliner J. D., Kinzler K. M., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53 associated protein in human sarcoma. Nature 1992; 358: 80–83
   PubMed Web of Science ®Google Scholar
• Hirama X, Koeffler H. P. Role of the cyclin-depen-dent kinase inhibitors in the development of cancer. Blood 1995; 86: 841–854
   PubMed Web of Science ®Google Scholar
• Cobrinik D., Lee M. H., Hannon G., Mulligan G., Bron-Son R. T., Dyson N., Harlow E., Beach D., Weinbert R. A., Jacks T. Shared role of the pRb-related p130 and p107 limb development. Genes Dev. 1996; 10: 1633–1644
   PubMed Web of Science ®Google Scholar
• Lee M. H., Williams B. O., Mulligan G., Mukai S., Bron-Son R. T., Dyson N., Harlow E., Jacks T. Targeted disruption of p107: functional relationship between p107 and Rb. Genes Dev. 1996; 10: 1621–1632
   PubMed Web of Science ®Google Scholar
• Thomas N. S. B., Pizzey A. R., Tiwari S., Williams C. D., Yang J. p130. p107. and pRb are differentially regulated in proliferating cells and during cell cycle arrest by α-interferon. J. Biol. Chem. 1998; 273: 23659–23667
   Google Scholar
• Beijersbergen R. L., Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim. Biophys. Acta 1996; 1287: 103–120
   PubMed Web of Science ®Google Scholar
• Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-b˜-induced cell cycle arrest. Nature 1994; 371: 257–261
   PubMed Web of Science ®Google Scholar
• Serrano M., Hannon G. J., Beach D. A new regulation motif in cell cycle control causing specific inhbition of cyclin D/CDK4. Nature 1993; 366: 704–707
   PubMed Web of Science ®Google Scholar
• Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–440
   PubMed Web of Science ®Google Scholar
• Batova A., Diccianni M. B., Nobori T., Vu T., Yu J., Bridgeman L., Yu A. L. Frequent deletion of the methylthioadenosine phosphorylase bene in T-cell acute lymphoblastic leukemia: strategies for enzyme targeted therapy. Blood 1996; 88: 3083–3090
   PubMed Web of Science ®Google Scholar
• Dnyling M. H., Bohlander S. K., Le Beau M. M., Olopade O. I. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hemataologic malignancies. Blood 1995; 86: 1931–1938
   PubMed Web of Science ®Google Scholar
• Iravani M., Dhaf R., Rice C. M. Methylation of the multi tumor suppressor gene-2[MTS2. CDKN1, p15(INK4B)] in childhood acute lymphoblastic leukemia. Oncogene 1997; 15: 2609–2614
   Google Scholar
• Batova A., Diccianni M. B., Yu J. C., Nobori T., Lunk M. P., Pullen J., Yu A. L. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 1997; 57: 832–836
   PubMed Web of Science ®Google Scholar
• Shah S. J., Taub J. W., Radewan T. L., Fu F., Moon D., Pollock B. H., Zhang L., Amylon M., Behm F. G., Pullen J., Ravindranath Y., Matherly L. H. Relationship of p15 and p16 gene deletions to elevated dihydrofolate reductase (DHFR) in childhood acute lymphoblastic leukemia (ALL). Abstracts, Annual Meeting for American Society for Hematology: Blood. 1998; 92: 220a
   Google Scholar
• Ahuja H. G., Jat P. S., Foti A., Bar-Eli M., Cline M. J. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 1991; 78: 3259–3268
   PubMed Web of Science ®Google Scholar
• Sauerbrey A., Stammler G., Zintl F., Volm M. Expression and prognostic value of the retinoblastoma tumour suppressor gene (RB-1) in childhood acute lymphoblastic leukaemia. Brit. J. Haematol. 1996; 94: 99–104
   PubMed Web of Science ®Google Scholar